ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Clomipramine. Initiate clomipramine pharmacotherapy at the lowest recommended dosage, and increase the dosage gradually as recommended while monitoring individual patient response. A variety of signs and symptoms have been associated with the abrupt discontinuation of clomipramine pharmacotherapy. Adjunctive clomipramine pharmacotherapy for the symptomatic management of obsessive-compulsive disorder can be continued, if required, for up to one year without loss of efficacy. Abrupt discontinuation of long-term clomipramine pharmacotherapy may occasionally produce abdominal pain, anxiety, diarrhea, headache, malaise, nausea, nervousness, and vomiting. Concurrent clomipramine and estrogen pharmacotherapy can result in the inhibition of the metabolism of clomipramine. Concurrent clomipramine pharmacotherapy with anticholinergics or other drugs that produce anticholinergic actions may result in exaggeration of anticholinergic actions.
